Skip to Main Content

Paper Details

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
BMC Cancer
14
2018
Author NameAffiliation
Kevin P WeinfurtDuke University School of Medicine
Jerald P RadichClinical Research Division, Fred Hutchinson Cancer Research Center
Vivian G OehlerClinical Research Division, Fred Hutchinson Cancer Research Center
Michael W DeiningerHuntsman Cancer Institute, The University of Utah
Neil P ShahUniversity of California at San Francisco
Jorge CortesUniversity of Texas MD Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2